カテゴリー： Grand View Research, 世界, 医療/バイオ

世界の爪白癬市場2023-2030：種類別（遠位爪甲下型爪白癬、表在性白色型爪白癬、近位爪甲下型爪白癬）、治療法別（経口、外用）、地域別

【英語タイトル】Onychomycosis Market Size, Share & Trends Analysis Report By Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis), By Treatment (Oral, Topical), By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23MR127）・商品コード：GRV23MR127
・発行会社（調査会社）：Grand View Research
・発行日：2023年2月
・ページ数：130
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥773,500見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥903,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,163,500見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
Grand View Research社の市場調査書によると、世界の爪白癬市場規模が、2023年から2030年の間にCAGR 4.56％増加し、2030年までに49.2億ドルへ達すると見込まれています。本書では、爪白癬の世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、産業の展望、競争状況、種類別（遠位爪甲下型爪白癬、表在性白色型爪白癬、近位爪甲下型爪白癬、その他）分析、治療別（経口、外用、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、企業情報などについてまとめています。なお、こちらに掲載されている企業情報には、Bausch Health Companies Inc.,、Gsk Plc、Abbott、F. Pfizer Inc.,、Bayer Ag、Teva Pharmaceutical Industries, Ltd.、Cipla Inc.、Novartis Ag、Sun Pharmaceutical Industries Ltd.、Merck & Co., Inc.などが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・産業の展望
・競争状況
・世界の爪白癬市場規模：種類別
- 遠位爪甲下型爪白癬の市場規模
- 表在性白色型爪白癬の市場規模
- 近位爪甲下型爪白癬の市場規模
- その他爪白癬の市場規模
・世界の爪白癬市場規模：治療別
- 経口治療の市場規模
- 外用治療の市場規模
- その他治療の市場規模
・世界の爪白癬市場規模：地域別
- 北米の爪白癬市場規模
- ヨーロッパの爪白癬市場規模
- アジア太平洋の爪白癬市場規模
- 中南米の爪白癬市場規模
- 中東・アフリカの爪白癬市場規模
・企業情報
❖ レポートの概要 ❖

Onychomycosis Market Growth & Trends

The global onychomycosis market is expected to reach USD 4.92 billion by 2030, expanding at a CAGR of 4.56% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual’s ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.

Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.

International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient’s condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.

Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world’s first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.

Onychomycosis Market Report Highlights

• Distal subungual onychomycosis segment dominated the market in 2022 and is attributable to the increasing prevalence and number of generic approvals by the FDA to meet the rising demands

• Topical segment is expected to show the fastest growth rate over the forecast period owing to ease of usage and administration which leads to increased patient compliance with treatment

• Players have an increased focus on acquiring specialized capacities that are highly capital-intensive to develop and maintain their competitive position

• North America held the largest market share in 2022 which can be attributed to better access to healthcare, the presence of a wide target population, and high adoption of treatment

❖ レポートの目次 ❖

Table of Contents

Chapter 1 Onychomycosis Market: Methodology And Scope
1.1 Market Segmentation
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
1.7 Global Market: Cagr Calculation
1.8 List Of Secondary Sources
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.10 List Of Abbreviations
Chapter 2 Onychomycosis Market: Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Onychomycosis Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Increasing Incidence Of Onychomycosis And Chronic Diseases
3.3.1.2 Rising Awareness About Treatment Of Onychomycosis
3.3.1.3 Escalating R&D Efforts By Players
3.3.1.4 Growing Geriatric Population And Diabetic Population
3.3.2 Market Restraint Analysis
3.3.2.1 Increasing Resistance To Antifungal Drugs
3.4 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.5 Industry Analysis – Porter’s
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
3.7.1 New Product Launch
3.7.2 Acquisition
3.7.3 Expansion
3.7.4 Partnerships
3.7.5 Marketing & Promotions
Chapter 4 Onychomycosis Market: Competitive Landscape
4.1 Recent Developments & Impact Analysis, By Key Market Participants
4.1.1 Ansoff Matrix
4.2 Company Categorization
4.2.1 Innovators
4.2.1.1 Market Differentiators
4.3 Vendor Landscape
4.3.1 List Of Key Distributors And Channel Partners
4.3.2 Key Customers
4.3.3 Key Company Market Share Analysis, 2022
4.4 Public Companies
4.4.1 Competitive Dashboard Analysis
4.5 Private Companies
4.5.1 List Of Key Emerging Companies
4.6 Regional Network Map
Chapter 5 Onychomycosis Market: Type Business Analysis
5.1 Definition And Scope
5.2 Type Market Share Analysis, 2022 & 2030
5.3 Global Onychomycosis Market, By Type, 2018 To 2030
5.4 Onychomycosis Market: Type Movement Analysis
5.5 Distal Subungual Onychomycosis
5.5.1 Distal Subungual Onychomycosis Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.6 White Superficial Onychomycosis
5.6.1 White Superficial Onychomycosis Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.7 Proximal Subungual Onychomycosis
5.7.1 Proximal Subungual Onychomycosis Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.8 Other Types
5.8.1 Other Types Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 6 Onychomycosis Market: Treatment Business Analysis
6.1 Definition And Scope
6.2 Treatment Market Share Analysis, 2022 & 2030
6.3 Global Onychomycosis Market, By Treatment, 2018 To 2030
6.4 Tuberculosis Therapeutics Market: Treatment Movement Analysis
6.5 Oral
6.5.1 Oral Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.6 Topical
6.6.1 Topical Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.7 Others
6.7.1 Others Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 7 Onychomycosis Market: Regional Business Analysis
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2022 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 MEA
7.6 Market Size, & Forecasts, Trend Analysis, 2022 To 2030
7.7 North America
7.7.1 North America Onychomycosis Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.7.2 U.S.
7.7.2.1 U.S. Onychomycosis Market, 2018 – 2030 (USD Million)
7.7.2.2 Key Country Dynamics
7.7.2.3 Regulatory Framework
7.7.2.4 Competitive Scenario
7.7.2.5 Import Export Scenario
7.7.2.6 Investments Scenario
7.7.3 Canada
7.7.3.1 Canada Onychomycosis Market, 2018 – 2030 (USD Million)
7.7.3.2 Key Country Dynamics
7.7.3.3 Regulatory Framework
7.7.3.4 Competitive Scenario
7.7.3.5 Import Export Scenario
7.7.3.6 Investments Scenario
7.8 Europe
7.8.1 Europe Onychomycosis Market, 2018 – 2030 (USD Million)
7.8.2 U.K.
7.8.2.1 U.K. Onychomycosis Market, 2018 – 2030 (USD Million)
7.8.2.2 Key Country Dynamics
7.8.2.3 Regulatory Framework
7.8.2.4 Competitive Scenario
7.8.2.5 Import Export Scenario
7.8.2.6 Investments Scenario
7.8.3 Germany
7.8.3.1 Germany Onychomycosis Market, 2018 – 2030 (USD Million)
7.8.3.2 Key Country Dynamics
7.8.3.3 Regulatory Framework
7.8.3.4 Competitive Scenario
7.8.3.5 Import Export Scenario
7.8.3.6 Investments Scenario
7.8.4 Spain
7.8.4.1 Spain Onychomycosis Market, 2018 – 2030 (USD Million)
7.8.4.2 Key Country Dynamics
7.8.4.3 Regulatory Framework
7.8.4.4 Competitive Scenario
7.8.4.5 Import Export Scenario
7.8.4.6 Investments Scenario
7.8.5 France
7.8.5.1 France Onychomycosis Market, 2018 – 2030 (USD Million)
7.8.5.2 Key Country Dynamics
7.8.5.3 Regulatory Framework
7.8.5.4 Competitive Scenario
7.8.5.5 Import Export Scenario
7.8.5.6 Investments Scenario
7.8.6 Italy
7.8.6.1 Italy Onychomycosis Market, 2018 – 2030 (USD Million)
7.8.6.2 Key Country Dynamics
7.8.6.3 Regulatory Framework
7.8.6.4 Competitive Scenario
7.8.6.5 Import Export Scenario
7.8.6.6 Investments Scenario
7.8.7 Russia
7.8.7.1 Russia Onychomycosis Market, 2018 – 2030 (USD Million)
7.8.7.3 Regulatory Framework
7.8.7.4 Competitive Scenario
7.8.7.5 Import Export Scenario
7.8.7.6 Investments Scenario
7.8.8 Denmark
7.8.8.1 Denmark Onychomycosis Market, 2018 – 2030 (USD Million)
7.8.8.2 Key Country Dynamics
7.8.8.3 Regulatory Framework
7.8.8.4 Competitive Scenario
7.8.8.5 Import Export Scenario
7.8.8.6 Investments Scenario
7.8.9 Sweden
7.8.9.1 Sweden Onychomycosis Market, 2018 – 2030 (USD Million)
7.8.9.2 Key Country Dynamics
7.8.9.3 Regulatory Framework
7.8.9.4 Competitive Scenario
7.8.9.5 Import Export Scenario
7.8.9.6 Investments Scenario
7.8.10 Norway
7.8.10.1 Norway Onychomycosis Market, 2018 – 2030 (USD Million)
7.8.10.2 Key Country Dynamics
7.8.10.3 Regulatory Framework
7.8.10.4 Competitive Scenario
7.8.10.5 Import Export Scenario
7.8.10.6 Investments Scenario
7.9 Asia Pacific
7.9.1 Asia-Pacific Onychomycosis Market, 2018 – 2030 (USD Million)
7.9.2 Japan
7.9.2.1 Japan Onychomycosis Market, 2018 – 2030 (USD Million)
7.9.2.2 Key Country Dynamics
7.9.2.3 Regulatory Framework
7.9.2.4 Competitive Scenario
7.9.2.5 Import Export Scenario
7.9.2.6 Investments Scenario
7.9.3 China
7.9.3.1 China Onychomycosis Market, 2018 – 2030 (USD Million)
7.9.3.2 Key Country Dynamics
7.9.3.3 Regulatory Framework
7.9.3.4 Competitive Scenario
7.9.3.5 Import Export Scenario
7.9.3.6 Investments Scenario
7.9.4 India
7.9.4.1 India Onychomycosis Market, 2018 – 2030 (USD Million)
7.9.4.2 Key Country Dynamics
7.9.4.3 Regulatory Framework
7.9.4.4 Competitive Scenario
7.9.4.5 Import Export Scenario
7.9.4.6 Investments Scenario
7.9.5 South Korea
7.9.5.1 South Korea Onychomycosis Market, 2018 – 2030 (USD Million)
7.9.5.2 Key Country Dynamics
7.9.5.3 Regulatory Framework
7.9.5.4 Competitive Scenario
7.9.5.5 Import Export Scenario
7.9.5.6 Investments Scenario
7.9.6 Thailand
7.9.6.1 Thailand Onychomycosis Market, 2018 – 2030 (USD Million)
7.9.6.2 Key Country Dynamics
7.9.6.3 Regulatory Framework
7.9.6.4 Competitive Scenario
7.9.6.5 Import Export Scenario
7.9.6.6 Investments Scenario
7.9.7 Australia
7.9.7.1 Australia Onychomycosis Market, 2018 – 2030 (USD Million)
7.9.7.2 Key Country Dynamics
7.9.7.3 Regulatory Framework
7.9.7.4 Competitive Scenario
7.9.7.5 Import Export Scenario
7.9.7.6 Investments Scenario
7.10 Latin America
7.10.1 Latin America Onychomycosis Market, 2018 – 2030 (USD Million)
7.10.2 Brazil
7.10.2.1 Brazil Onychomycosis Market, 2018 – 2030 (USD Million)
7.10.2.2 Key Country Dynamics
7.10.2.3 Regulatory Framework
7.10.2.4 Competitive Scenario
7.10.2.5 Import Export Scenario
7.10.2.6 Investments Scenario
7.10.3 Mexico
7.10.3.1 Mexico Onychomycosis Market, 2018 – 2030 (USD Million)
7.10.3.2 Key Country Dynamics
7.10.3.3 Regulatory Framework
7.10.3.4 Competitive Scenario
7.10.3.5 Import Export Scenario
7.10.3.6 Investments Scenario
7.10.4 Argentina
7.10.4.1 Argentina Onychomycosis Market, 2018 – 2030 (USD Million)
7.10.4.2 Key Country Dynamics
7.10.4.3 Regulatory Framework
7.10.4.4 Competitive Scenario
7.10.4.5 Import Export Scenario
7.10.4.6 Investments Scenario
7.11 MEA
7.11.1 MEA Onychomycosis Market, 2018 – 2030 (USD Million)
7.11.2 South Africa
7.11.2.1 South Africa Onychomycosis Market, 2018 – 2030 (USD Million)
7.11.2.2 Key Country Dynamics
7.11.2.3 Regulatory Framework
7.11.2.4 Competitive Scenario
7.11.2.5 Import Export Scenario
7.11.2.6 Investments Scenario
7.11.3 Saudi Arabia
7.11.3.1 Saudi Arabia Onychomycosis Market, 2018 – 2030 (USD Million)
7.11.3.2 Key Country Dynamics
7.11.3.3 Regulatory Framework
7.11.3.4 Competitive Scenario
7.11.3.5 Import Export Scenario
7.11.3.6 Investments Scenario
7.11.4 UAE
7.11.4.1 UAE Onychomycosis Market, 2018 – 2030 (USD Million)
7.11.4.2 Key Country Dynamics
7.11.4.3 Regulatory Framework
7.11.4.4 Competitive Scenario
7.11.4.5 Import Export Scenario
7.11.4.6 Investments Scenario
7.11.5 Kuwait
7.11.5.1 Kuwait Onychomycosis Market, 2018 – 2030 (USD Million)
7.11.5.2 Key Country Dynamics
7.11.5.3 Regulatory Framework
7.11.5.4 Competitive Scenario
7.11.5.5 Import Export Scenario
7.11.5.6 Investments Scenario
Chapter 8 Onychomycosis Market: Company Profiling
8.1 Company Profiles
8.1.1 Bausch Health Companies Inc.,
8.1.1.1 Company Overview
8.1.1.2 Financial Performance
8.1.1.3 Product Benchmarking
8.1.1.4 Strategic Initiatives
8.1.2 Gsk Plc
8.1.2.1 Company Overview
8.1.2 2.Financial Performance
8.1.2.3 Product Benchmarking
8.1.2.4 Strategic Initiatives
8.1.3 Abbott
8.1.3.1 Company Overview
8.1.3.2 Financial Performance
8.1.3.3 Product Benchmarking
8.1.3.4 Strategic Initiatives
8.1.4 F. Pfizer Inc.,
8.1.4.1 Company Overview
8.1.4.2 Financial Performance
8.1.4.3 Product Benchmarking
8.1.4.4 Strategic Initiatives
8.1.5 Bayer Ag
8.1.5.1 Company Overview
8.1.5.2 Financial Performance
8.1.5.3 Product Benchmarking
8.1.5.4 Strategic Initiatives
8.1.6 Teva Pharmaceutical Industries, Ltd.
8.1.6.1 Company Overview
8.1.6.2 Financial Performance
8.1.6.3 Product Benchmarking
8.1.6.4 Strategic Initiatives
8.1.7 Cipla Inc.
8.1.7.1 Company Overview
8.1.7.2 Financial Performance
8.1.7.3 Product Benchmarking
8.1.7.4 Strategic Initiatives
8.1.8 Novartis Ag
8.1.8.1 Company Overview
8.1.8.2 Financial Performance
8.1.8.3 Product Benchmarking
8.1.8.4 Strategic Initiatives
8.1.9 Sun Pharmaceutical Industries Ltd.
8.1.9.1 Company Overview
8.1.9.2 Financial Performance
8.1.9.3 Product Benchmarking
8.1.9.4 Strategic Initiatives
8.1.10 Merck & Co., Inc.
8.1.10.1 Company Overview
8.1.10.2 Financial Performance
8.1.10.3 Product Benchmarking
8.1.10.4 Strategic Initiatives



★調査レポート[世界の爪白癬市場2023-2030：種類別（遠位爪甲下型爪白癬、表在性白色型爪白癬、近位爪甲下型爪白癬）、治療法別（経口、外用）、地域別] (コード：GRV23MR127)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の爪白癬市場2023-2030：種類別（遠位爪甲下型爪白癬、表在性白色型爪白癬、近位爪甲下型爪白癬）、治療法別（経口、外用）、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の結核治療薬市場2023-2030：疾患種類別（活動性結核、潜在性結核）、治療法別、投与経路別、剤形別、流通チャネル別、地域別
    GRV23MR044 / Grand View Research / 2023年2月 / Grand View Research社の市場調査書によると、世界の結核治療薬市場規模が、2023年から2030年の間にCAGR 5.09％増加し、2030年までに29.9億ドルへ達すると見込まれています。本書では、結核治療薬の世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、産業の展望、競合状況、疾患種類別（活動性結核、潜在性結核）分析、治療法別（一次治療、二次治療）分析、投与経路別（経口、非経口、その他）分析、剤形別（錠剤、カプセル、注射剤、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、企業情報などについてまとめています。なお、こちらに掲載されている企業情報には、Astrazeneca、Johnson &...
  • 世界のT細胞療法市場2023-2030：治療法別（CAR-T細胞療法、TIL療法）、疾患別（血液悪性腫瘍（リンパ腫））
    GRV23MR041 / Grand View Research / 2023年2月 / Grand View Research社の市場調査書によると、世界のT細胞療法市場規模が、2023年から2030年の間にCAGR 17.6％増加し、2030年までに308.3億ドルへ達すると見込まれています。本書では、T細胞療法の世界市場を調査対象とし、調査手法、エグゼクティブサマリー、市場変動・動向・範囲、様式別（研究、商業）分析、治療法別（CAR-T細胞療法、TCR療法、TIL療法）分析、疾患別（血液悪性腫瘍、固形腫瘍、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などについてまとめています。なお、こちらに掲載されている企業情報には、Novartis AG、Gilead...
  • 世界の抗体フラグメント市場2022-2030：特異性別（モノクローナル抗体、ポリクローナル抗体）、種類別、治療法別、用途別、地域別
    GRV22SP096 / Grand View Research / 2022年8月25日 / Grand View Research社の最新調査レポートによると、世界の抗体フラグメント市場規模は2030年までに113.6憶ドルに達っし、2022年から2030年にかけて年平均5.9％成長すると予測されています。本書では、抗体フラグメントの世界市場を多面的に調査し、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、特異性別（モノクローナル抗体、ポリクローナル抗体）分析、種類別（FAB、scFv、sdAb、その他）分析、治療法別（モノクローナル抗体、プラックスバインド、ラニビズマブ、セルトリズマブペゴル、その他）分析、用途別（癌、免疫不全、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成でお届けいたします。なお、本書に掲載されている企業情報には、Pfizer Inc、Sanofi、Albynx、Novartis AG、Genentech,...
  • 世界の男性不妊症市場2022-2030：検査別（DNA断片化法、酸化ストレス解析、顕微鏡検査）、治療法別、地域別
    GRV22JL053 / Grand View Research / 2022年5月12日 / グランドビューリサーチ社は、世界の男性不妊症市場規模が2022年から2030年の間に年平均4.9％成長し、2030年までに59億ドルに達すると予測しています。本調査レポートでは、男性不妊症の世界市場について調査し、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、検査別（DNA断片化法、酸化ストレス解析、顕微鏡検査、精子凝集、その他）分析、治療法別（ART・精索静脈瘤手術、薬物治療）分析、地域別分析、競争分析、推奨事項などを掲載しています。本調査レポートでは、EMD Serono, Inc.、Endo International plc、Sanofi、Bayer...
  • 世界の脊髄性筋萎縮症治療市場2022-2030：種類別（1型、2型）、治療法別（遺伝子治療、薬剤）、治療薬別（スピンラザ、ゾルゲンマ）、投与経路別、地域別
    GRV22DC051 / Grand View Research / 2022年11月3日 / Grand View Research社は、世界の脊髄性筋萎縮症治療市場規模が、2022年から2030年の間に年平均18.6％成長し、2030年までに180億ドルに達すると予測しています。当調査レポートでは、脊髄性筋萎縮症治療の世界市場について総合的に調査・分析を行い、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、種類別（1型、2型、3型、4型）分析、治療法別（遺伝子治療、薬剤治療）分析、治療薬別（スピンラザ、ゾルゲンマ、エヴリスディ、その他）分析、投与経路別（経口、注射）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、競争状況などの構成でまとめています。なお、当書に掲載されている企業情報には、Biogen、Novartis AG、Ionis Pharmaceuticals...

    • ◆H&Iグローバルリサーチのお客様（例）◆